Blue Matter Blog
April 8, 2019
Over the past few decades in oncology, targeted therapies—and the tests that identify which tumors will be sensitive to them—have significantly advanced the standard of care in several key settings. However, precision medicine will not achieve its full potential in oncology without broader success in pharmaceutical and diagnostic development, and better integration of both into …
By pressing the “Accept Cookies” button, the user accepts all Cookies on the Website. View our Cookie Statement.